Are not seeking aggressive appetite suppression
When prescribed to the right candidates, patients achieve dramatic weight loss results in a way that is both healthy and sustainable
- Durability: Benefits sustained across both trials, with improvements in cardiometabolic markers
If you are losing weight steadily at 0.5 mg (20 units, for example), your provider might suggest staying at that dose rather than increasing
Among these, liraglutide in the LEADER study, semaglutide in the SUSTAIN-6, albiglutide in the Harmony Outcomes, dulaglutide in the REWIND, and efpeglenatide in the AMPLITUDE-O exhibited significant beneficial effects on 3-point major adverse cardiac events (3P-MACE: death from CV disease, non-fatal myocardial infarction, and non-fatal stroke), the primary end point of each study, compared to the placebo group, respectively